Personalized medicine

Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer

Retrieved on: 
Thursday, October 13, 2022
Regulatory T cell, McKinsey & Company, Therapy, Growth, Infection, IND, Degenerative disease, Scleroderma, Patient, Synthetic biology, Research, Investigational New Drug, NIH, Multimedia, CAR, Regulation, Transplant, Lupus nephritis, R, Industry, National, CEO, Gilead, Health, Myopathy, CD19, Autoimmunity, Intellia Therapeutics, Inflammation, Personalized medicine, BD, Engineering, Pharmaceutical industry, Management, Vaccine, Novartis

EMERYVILLE, Calif., Oct. 13, 2022 /PRNewswire/ --  Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company's chief executive officer (CEO). Dr. Maag succeeds Dominic Borie, M.D., Ph.D., who has been named Kyverna's president of research and development (R&D). Dr. Maag also joins Kyverna's board of directors.

Key Points: 
  • "We are thrilled to welcome Peter as Kyverna's new CEO," said Ian Clark, chair of Kyverna's board of directors.
  • Dr. Maag has more than 20 years of executive management experience in the pharmaceutical and diagnostic industry.
  • "I am passionate about patient care and am honored to be appointed to lead Kyverna and this extraordinarily talented team.
  • Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases.

Global Whole Exome Sequencing Market Report 2022: Personalized Medicine to Fuel the Demand for WES Technology - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022
Health, Genetics, Observation, Agriculture, Biotechnology, Development, Medication, Hospital, Co-production (public services), Risk, Kits, Research, Sanger sequencing, Academy, Geography, Growth, Product, Ansoff Matrix, Industry, Market development, USD, Investment, Drug discovery, Others, Ion semiconductor sequencing, SWOT, SBS, Personalized medicine, CAGR, Fine chemical, Medical device, Retail, Risk management, Technology, System

The Global Whole Exome Sequencing [WES] Market is segmented based on Products and Services, Technology, Applications, End-user, and Geography.

Key Points: 
  • The Global Whole Exome Sequencing [WES] Market is segmented based on Products and Services, Technology, Applications, End-user, and Geography.
  • By Technology, the market is classified into Sequencing By Synthesis (SBS), ION Semiconductor Sequencing, and Other Technologies.
  • The report presents a detailed Ansoff matrix analysis for the Global Whole Exome Sequencing [WES] Market.
  • The report offers a comprehensive evaluation of the Global Whole Exome Sequencing [WES] Market.

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

Retrieved on: 
Monday, August 22, 2022
Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Biometrics, Managed Care, Health, Oncology, Partnership, Co-leader of the Scottish Green Party, CEO, Cancer, Catalog, Safety, National Institute, Device, Grant, National Institute of Standards and Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Horizon Discovery, NIST, Food and Drug Administration, Doctor of Philosophy, FDA Center for Devices and Radiological Health, NGS, SRS, CRISPR, Food, Diagnosis, DNA, NIH, PerkinElmer, National, National Philanthropic Trust, National Institutes of Health, MD, MDIC, SRSS, Gordon, Center, FDA, Therapy, Industry, Data, Personalized medicine, Efficiency, Medical device, Pharmaceutical industry, Quidel Corporation, Technology, Illumina

The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators.

Key Points: 
  • The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators.
  • These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process.
  • But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process, said Andrew Fish, President and CEO, MDIC.
  • Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle.

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors

Retrieved on: 
Tuesday, August 9, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Agilent Technologies, Lung cancer, Ageing, TRI, Sequoia Capital, Associate professor, Trial of the century, Internal medicine, Immunology, OS, NCCN, Female, Division, CBM, Nebraska Medicine, Group, Artificial intelligence, Research, Department, NSCLC, UnitedHealth Group, Patient, Male, Large-cell lung carcinoma, Nominal interest rate, Veterans' affairs, Lung, International Association, Personalized medicine, Â, University of Minnesota, Physician, Software, Transplant, University, University of Nebraska Medical Center, Conference, Sex, Pharmaceutical industry, Medical device, Hematology

In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.

Key Points: 
  • In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.
  • The myCare-203A study found that the personalized approach of Cellworks Singula TRI produces a more precise therapeutic decision guide for patients with NSCLC.
  • The myCare-203A study shows us that the Cellworks Biosimulation Platform and Singula TRI can streamline the treatment decision-making process and improve NSCLC patient outcomes through personalized therapy response predictions.
  • These results show that physicians can use Cellworks Singula TRI scores to more precisely guide therapeutic decisions for individual patients with NSCLC.

Laboratory Industry Doesn't Forget COVID-19, But Shifts Focus to Other Health Conditions at AACC 2022 in Chicago

Retrieved on: 
Thursday, July 28, 2022
LRE Map, Association, Legislation, Delta-8-Tetrahydrocannabinol, Ethics, Autonomous detection system, Pediatrics, Multimedia, University of Washington Department of Bioengineering, Roche, IVD, Siemens Healthineers, Professor, Warfarin, Acquisition, Genomics, Doctor of Philosophy, Research, NASH, Cancer, AACC, University of Missouri–Kansas City School of Medicine, Mayo, Automation, AI, NAFLD, COVID-19, Liver disease, DC-1, Liver, Blood, ELF, Kidney disease, Abbott, University, Beckman, Health informatics, Thermo Fisher Scientific, Hematology, GC, Clinical professor, Risk, TLA, American Association, Approximation error, Movement, Kidney, MD, FTIR, Patient, Department, LDT, Cirrhosis, Pharmaceutical industry, Medical device, Child, Mercy, Science, Personalized medicine

CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.

Key Points: 
  • CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.
  • Kalorama Information analysts attended sessions and observed trends at the AACC meeting, noting that very little focus was related to the recent pandemic.
  • Perhaps a vestige of the COVID-19 pandemic was a focus on better and faster workflows, automation and other products.
  • AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes' trial, moderated the discussion.

Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding Patient Decisions with Mass Spectrometry, and Much More to Be Explored at the 2022 AACC Annual Scientific Meeti

Retrieved on: 
Sunday, July 24, 2022
DNA, University of California, San Diego Performance-Based Skills Assessment, Brain, Trust, University, Harvard University, Precision medicine, Public health, Baylor University, Protein, Mass spectrometry, Health, MasSpec Pen, Research, Artificial intelligence, Molecular medicine, Wiltshire Historic Buildings Trust, Press Ganey Associates, Baylor College of Medicine, Quality of life, Technology, AACC, Patient, Neurology, Harvard T.H. Chan School of Public Health, Informatics, RNA, Health policy, Medical device, Medical imaging, Health care, Personalized medicine

From July 24-28 in Chicago, the meeting's 250-plus sessions will deliver insights on a broad range of timely healthcare topics.

Key Points: 
  • From July 24-28 in Chicago, the meeting's 250-plus sessions will deliver insights on a broad range of timely healthcare topics.
  • Highlights include discussions exploring the use of artificial intelligence (AI) in personalized medicine, advances in multiplexed genomic sequencing and imaging, real-life applications of human brain organogenesis, how to build trust with patients, and guiding clinical decisions with mass spectrometry.
  • Precision medicine involves tailoring treatments to individual patients and, increasingly, clinicians are using AI in their clinical prediction models to do this.
  • Thanks to advances in multiplexed genomic sequencing and imaging, we can identify small but crucial differences in DNA, RNA, proteins, and more.

Outlook on the Bioinformatics Global Market to 2027 - Blockchain Technology and Cloud Computing Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022
Biotechnology, Biometrics, Health, Pharmaceutical, Health Technology, Knowledge, Drug discovery, Porter's five forces analysis, Investment, CAGR, Product, Ansoff Matrix, Observation, Industry, SWOT, Geography, Transcriptomics technologies, Risk, Growth, Emotion, Impact, Ortho Clinical Diagnostics, USD, Personalized medicine, Co-production (public services), COVID-19, Market development, Competitive analysis, Retail, Risk management, Pharmaceutical industry, Marketing, Medical device, Proteomics, Genomics, Metabolomics

The Global Bioinformatics Market is estimated to be USD 12.28 Bn in 2022 and is projected to reach USD 24.85 Bn by 2027, growing at a CAGR of 15.14%.

Key Points: 
  • The Global Bioinformatics Market is estimated to be USD 12.28 Bn in 2022 and is projected to reach USD 24.85 Bn by 2027, growing at a CAGR of 15.14%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Bioinformatics Market stakeholders.
  • The report analyses the Global Bioinformatics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Growing Applications of Bioinformatics in Proteomics and Drug Discovery, Clinical Diagnostics and Personalized Medicine
    The Global Bioinformatics Market is segmented based on Bioinformatics Platform, Applications, End-User and Geography.

The Worldwide Transcriptomics Industry is Expected to Reach $9.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Health, Genetics, Diagnosis, A-DNA, National, Biotechnology, Biology, Research, Technology, Real-time polymerase chain reaction, Gene, Lists of diseases, Biomarker, Transcriptome, SAGE, Growth, Gene expression, Application, Cancer, Industry, Tuberculosis, Method, NIH, Bias, CAGR, Personalized medicine, Drug discovery, Toxicity, RNA, Polymerase chain reaction, Cardiovascular disease, DNA, Reverse transcriptase, National Human Genome Research Institute, PCR, Component, Vaccine, Government, EST, Knowledge, Transcriptomics technologies, RNA interference, Medical imaging, Pharmaceutical industry

The Global Transcriptomics Market size is expected to reach $9.4 billion by 2027, rising at a market growth of 7.6% CAGR during the forecast period.

Key Points: 
  • The Global Transcriptomics Market size is expected to reach $9.4 billion by 2027, rising at a market growth of 7.6% CAGR during the forecast period.
  • Quantitative reverse transcription, or q PCR, is a technique for detecting the presence and quantity of RNA by turning it into cDNA.
  • It is named reverse transcription since it is carried out with the help of a polymerase chain reaction.
  • In addition, transcriptomics data from RNA sequencing has low genome coverage and strong amplification bias, making data interpretation difficult, particularly without effective bioinformatics tools.

Fuzionaire Diagnostics Enters Agreement with McMaster University to Expand Capabilities in Developing Theranostic Radiopharmaceuticals

Retrieved on: 
Wednesday, June 29, 2022
Other Health, Research, Pharmaceutical, Oncology, Training, Other Education, University, Education, Science, Biotechnology, Other Science, Health, Associate professor, University, Personalized medicine, Ligand, Student, Cancer, McMaster, Chemistry, McMaster University, PET, Neoplasm, Doctor of Philosophy, Radiochemistry, Principal investigator, Diagnosis, Medical imaging, Nobel, California Institute of Technology

Fuzionaire Diagnostics, Inc. ("Fuzionaire Dx") today announced a collaborative research agreement with McMaster University ("McMaster") under which theranostic radiopharmaceuticals developed with Fuzionaire Dx's HetSiFA platform will be evaluated at McMaster's comprehensive preclinical nuclear medicine facilities.

Key Points: 
  • Fuzionaire Diagnostics, Inc. ("Fuzionaire Dx") today announced a collaborative research agreement with McMaster University ("McMaster") under which theranostic radiopharmaceuticals developed with Fuzionaire Dx's HetSiFA platform will be evaluated at McMaster's comprehensive preclinical nuclear medicine facilities.
  • The collaboration expands Fuzionaire Dxs capabilities to evaluate oncologic theranostics made from its HetSiFA platform.
  • Fuzionaire Dx creates theranostic candidates by combining its HetSiFAs, or heteroaromatic silicon-fluoride acceptors, with cancer-targeting peptides and other ligands.
  • McMaster University is among Canadas most research-intensive universities and is consistently ranked as one of the worlds Top 100 universities.

RNA Analysis/Transcriptomics Global Market Research Report 2022: Microarrays, Sequencing, PCR, RNA Interference, Clinical Diagnostics, Drug Discovery, Toxicogenomics, Comparative Transcriptomics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Software, Technology, Health, Medical Devices, Sigma-Aldrich, NGS, US, Technology, Illumina, Inc., Personalized medicine, Transcriptome, Thermo Fisher Scientific, 10x Genomics, RNA-Seq, Software, RNA, RNA interference, Environment, Organization, US FDA, Library, Growth, Agilent Technologies, Acquisition, Diagnosis, Drug discovery, GE Healthcare, Application, PMC, Genomics, Medicinal plants, Vaccine, Dietary supplement, Illumina, Alex Cartana

The RNA analysis/ transcriptomics market consists of sales of RNA analysis products and related services by entities (organizations, sole traders, and partnerships) that provide RNA analysis.

Key Points: 
  • The RNA analysis/ transcriptomics market consists of sales of RNA analysis products and related services by entities (organizations, sole traders, and partnerships) that provide RNA analysis.
  • Technological advancements and innovations in RNA analysis are emerging trends in the RNA analysis/ transcriptomics market.
  • Global RNA Analysis/ Transcriptomics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.3.
  • Global RNA Analysis/ Transcriptomics Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion